Rimadyl
Disclaimer: This site has been created by www.MedicAnimal.com for information purposes only. MedicAnimal is a proud retailer of Rimadyl but is not affiliated with or related to the manufacturer of Rimadyl and the contents of this site are neither sponsored or endorsed by the manufacturer of Rimadyl.
Introduction
1. Rimadyl Palatable Tablets 20mg, 50mg and 100mg
2. Rimadyl Tablets 20mg and 50mg
3. Rimadyl Granules 8.75% w/v (2.4g)
Presentation
1. Rimadyl Palatable Tablets 20mg, 50mg and 100mg
Rimadyl Palatable Tablets for dogs are square light brown tablets scored down the middle containing as active ingredient either 20 mg, 50 mg or 100 mg carprofen.
2. Rimadyl Tablets 20mg and 50mg
Rimadyl Tablets are round white tablets scored down the middle containing as active ingredient either 20 mg or 50 mg carprofen.
3. Rimadyl Granules 8.75% w/v (2.4g)
White, free-flowing granules containing carprofen 8.75% w/w.
Uses
1. Rimadyl Palatable Tablets 20mg, 50mg and 100mg
For analgesia and reduction of chronic inflammation, for example in degenerative joint disease of the dog. Rimadyl Palatable Tablets can also be used in the management of post-operative pain in dogs.
2. Rimadyl Tablets 20mg and 50mg
For analgesia and reduction of chronic inflammation, for example in degenerative joint disease of the dog. Rimadyl tablets can also be used in the management of post-operative pain in dogs.
3. Rimadyl Granules 8.75% w/v (2.4g)
Carprofen is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. In horses and ponies it is indicated for analgesic and anti-inflammatory action in musculo-skeletal disorders and after surgery.
Dosage & administration
1. Rimadyl Palatable Tablets 20mg, 50mg and 100mg
For oral administration. The tablets are palatable and are willingly consumed by most dogs when offered.
An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given as a single dose or in two equally divided doses. Subject to clinical response the dose may be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single daily dose. To extend analgesic and anti-inflammatory cover post operatively, parenteral therapy with Rimadyl Small Animal Injection may be followed with Rimadyl Palatable Tablets at 4mg/kg/day for up to 5 days.
Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.
2. Rimadyl Tablets 20mg and 50mg
For oral administration.
An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given as a single dose or in two equally divided doses. Subject to clinical response the dose may be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single daily dose. To extend analgesic and anti-inflammatory cover post operatively, parenteral therapy with Rimadyl Injection may be followed with Rimadyl tablets at 4mg/kg/day for up to 5 days.
Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.
3. Rimadyl Granules 8.75% w/v (2.4g)
The recommended dosage is 0.7 mg carprofen per kg bodyweight. In all cases it is recommended that this be provided initially by an intravenous injection of carprofen, followed by once daily oral administration of the granules for up to 4 or 9 days according to clinical response. One sachet of Rimadyl Granules treats 300 kg bodyweight. For animals below 150 kg the use of half a sachet is recommended.
Rimadyl Granules should be administered with a little feed, mixed in to ensure the full dose is eaten.
Price comparison
Contra-indications, warnings, etc.
1. Rimadyl Palatable Tablets 20mg, 50mg and 100mg
The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog and the therapeutic index is narrower. In the absence of specific data the use of Rimadyl Palatable Tablets in the cat is contra-indicated.
Do not exceed the stated dose.
Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.
Use in dogs less than 6 weeks of age, or in aged dogs, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
In the absence of any specific studies in pregnant bitches, such use is not indicated.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
For animal treatment only.
Due to the palatable nature of the tablets, store in a secure location. Severe adverse reaction may occur if large quantities are ingested. If you suspect your dog has consumed Rimadyl Palatable Tablets above the labelled dose, please contact your veterinarian.
There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.
In the event of accidental ingestion of the tablets, seek medical advice and show the doctor what has been taken.
Wash hands after handling the product.
2. Rimadyl Tablets 20mg and 50mg
The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog and the therapeutic index is narrower. In the absence of specific data the use of Rimadyl Tablets in the cat is contra-indicated.
Do not exceed the stated dose.
Do not administer other NSAIDs concurrently or within 24 hours of each other. Do not administer in conjunction with glucocorticoids.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.
Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
In the absence of any specific studies in pregnant target bitches, such use is not indicated.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.
For animal treatment only.
In the event of accidental ingestion of the tablets, seek medical advice and show the doctor what has been taken.
Wash hands after handling the product.
3. Rimadyl Granules 8.75% w/v (2.4g)
For oral administration only.
For specific information about the time which must elapse between treatment and competition, veterinary surgeons are advised to consult the authority responsible for the competition in question (e.g. the Jockey Club in the case of racing in the UK).
Do not exceed the stated dose or the duration of treatment.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.
Do not use in animals suffering from cardiac, hepatic, renal disease where there is a possibility of gastro-intestinal ulceration or bleeding or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Use in any animal less than 6 weeks of age, or in aged animals, may involve additional risk. If such a use cannot be avoided animals may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potential nephrotoxic drugs should be avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
In the absence of any specific studies in pregnant target animals, such use is not indicated.
There is no specific antidote for carprofen overdosage but general supportive therapy as applied to clinical overdosage with NSAIDs should be applied.
For animal treatment only.
Withdrawal period
Not for use in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.
Operator warnings
Wash hands after use. Avoid inhalation of the product.
Pharmaceutical precautions
1. Rimadyl Palatable Tablets 20mg, 50mg and 100mg
Do not store above 25°C. Store in a dry place. Protect from light. Keep out of reach of children.
Any unused product or waste materials should be disposed of in accordance with national requirements.
2. Rimadyl Tablets 20mg and 50mg
Store in a dry place. Protect from light. Keep out of reach of children.
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
3. Rimadyl Granules 8.75% w/v (2.4g)
Do not store above 25°C. Protect from light. Store in a dry place.
Any unused, opened sachets should be discarded at the end of a course of treatment.
Any unused product or waste material should be disposed of in accordance with national requirements.
Keep out of reach of children.
Packaging quantities
1. Rimadyl Palatable Tablets 20mg, 50mg and 100mg
Containers of 14, 30 or 100 tablets x 20 mg, 14, 30 or 100 tablets x 50 mg, 14, 30 or 100 tablets x 100 mg
2. Rimadyl Tablets 20mg and 50mg
Containers of 100 × 20 mg, 100 × 50 mg and 500 × 50 mg tablets.
3. Rimadyl Granules 8.75% w/v (2.4g)
Cartons containing 20 sachets. Each sachet contains 2.4 g Rimadyl Granules (210 mg carprofen).
Further information
1. Rimadyl Palatable Tablets 20mg, 50mg and 100mg
Experimental and clinical evidence suggests that for carprofen in the dog gastro-intestinal tract ulceration is rare, and only occurs at dosages well above the therapeutic dose.
Following repeated therapeutic dosing for 8 weeks, carprofen has been shown to have no detrimental effect on chronically arthritic canine cartilage in a model of canine osteoarthritis.
In addition, therapeutic concentrations of carprofen have been demonstrated (in vitro) to increase proteoglycan synthesis in chondrocytes from canine arthritic cartilage.
Stimulation of proteoglycan synthesis will narrow the difference between the rate of degeneration and regeneration of cartilage matrix resulting in a slowing of the progression of cartilage loss.
2. Rimadyl Tablets 20mg and 50mg
Experimental and clinical evidence suggests that for carprofen in the dog gastro-intestinal tract ulceration is rare, and only occurs at dosages well above the therapeutic dose.
3. Rimadyl Granules 8.75% w/v (2.4g)
Both carprofen and warfarin may be bound to plasma proteins. Limited evidence indicates that binding is at different sites thus enabling concurrent use, but the clinical situation must be monitored carefully.
Disclaimer
This site has been created by www.MedicAnimal.com for information purposes only. MedicAnimal is a proud retailer of Rimadyl but is not affiliated with or related to the manufacturer of Rimadyl and the contents of this site are neither sponsored or endorsed by the manufacturer of Rimadyl.
